Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 11, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive TreatmentIncreased Patient Demand, Manufacturing Capacity and Time...
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 06, 2022 16:15 ET
|
Allogene Therapeutics, Inc.
ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501AProtocol Supported by Clinical...
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
September 23, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
August 09, 2022 16:02 ET
|
Allogene Therapeutics, Inc.
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2...
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
August 03, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
July 12, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
June 08, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of...
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 19, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with CancerFindings Underscore Potential of Allogeneic...
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal
May 09, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics,...